EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

AI in CGT needs AI-worthy data, not just better models

Gabriela Lenarczyk

Cell and Gene Therapy Insights · 31.07.2026 · 12 (6) · 657–661

DOI: 10.18609/cgti.2026.079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 31.07.2026. Verfasst von Gabriela Lenarczyk. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“The datasets underpinning CGT workflows, and the infrastructures that generate and connect them, must become AI-worthy before AI can matter at scale.”AI is widely positioned to transform cell and gene therapy (CGT), but its impact is limited less by an algorithmic deficit than by an AI-worthiness’ deficit: the field’s fragmented and poorly documented datasets are rarely governed, interoperable, and provenance-aware enough to support trustworthy AI. Drawing on the AI Act and the European Health Data Space, this piece argues that CGT developers, manufacturers, and clinical institutions should prioritize disciplined data stewardship now, because the datasets underpinning CGT workflows must become AI-worthy before AI can matter at scale.

Zitieren

APA

Lenarczyk, G. (2026). AI in CGT needs AI-worthy data, not just better models. Cell and Gene Therapy Insights, 12(6), 657–661. https://doi.org/10.18609/cgti.2026.079

Vancouver

Lenarczyk G. AI in CGT needs AI-worthy data, not just better models. Cell and Gene Therapy Insights. 2026;12(6):657–661. doi:10.18609/cgti.2026.079

BibTeX
@article{Lenarczyk2026,
  author = {Lenarczyk, Gabriela},
  title = {AI in CGT needs AI-worthy data, not just better models},
  journal = {Cell and Gene Therapy Insights},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {657–661},
  doi = {10.18609/cgti.2026.079}
}
Kostenlos starten →